Low-Dose Sublingual Ketamine for the Treatment of Raynaud's Phenomenon.
Study at a glance
AI-extracted from the abstract| Characteristics | Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | A woman with primary Raynaud's phenomenon and treatment-resistant depression |
| Intervention | low-dose sublingual ketamine |
| Dose | low-dose |
| Topics | Esketamine Ketamine |
| Keywords | Anti-inflammatory drugs Cold sensitivity Low-dose ketamine Microvascular perfusion Numbness Peripheral vasodilation Raynaud's phenomena Skin color Skin texture Tingling Raynaud's syndrome Sublingual ketamine Vascular disorders |
| Key findings | Low-dose sublingual ketamine treatment for depression was associated with significant improvement in Raynaud's phenomenon symptoms. |
Abstract
Raynaud's phenomenon is a vascular disorder characterized by episodic vasospasm of small arteries, primarily affecting the hands and feet. Standard treatment strategies typically include lifestyle modifications to avoid cold exposure and stress, alongside pharmacological interventions aimed at increasing blood flow and reducing vascular constriction. Ketamine, an FDA-approved anesthetic since 1970, exhibits analgesic and vasodilatory properties that may enhance perfusion. This case report describes a woman with primary Raynaud's phenomenon whose symptoms improved significantly during treatment with low-dose sublingual ketamine prescribed for treatment-resistant depression. Further research into the use of this safe and inexpensive medicine as a treatment for Raynaud's phenomenon is recommended.
Comparable studies
Other case reports and case series on ketamine, most cited first.
Citations in the library
Cites 7
- mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists Science August 19, 2010
- Side-effects associated with ketamine use in depression: a systematic review. The Lancet Psychiatry 2018
- Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments Proceedings of the National Academy of Sciences November 27, 2023
- At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. Journal of Affective Disorders July 1, 2022
- Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: A retrospective study of off-label, at-home use Frontiers in Psychiatry September 28, 2022
and 2 more in the library